Recombinant human apolipoprotein    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
79Homozygous familial hypercholesterolemia2

79. Homozygous familial hypercholesterolemia    [ 128 clinical trials,   105 drugs,   (DrugBank: 29 drugs),   8 drug target genes,   15 drug target pathways]
Searched query = "Homozygous familial hypercholesterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 128 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-003998-28-NL
(EUCTR)
28/02/201214/11/2011Effect of CER-001 on blockage of arteries (plaque) in subjects with homozygous familial hypercholesterolemiaModifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-Label Study of the Effects of CER-001 on Plaque Volume in Subjects with Homozygous Familial Hypercholesterolemia (HoFH) - MODE homozygous familial hypercholesterolemia
MedDRA version: 16.0;Level: LLT;Classification code 10020604;Term: Hypercholesterolemia;System Organ Class: 100000004861;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Recombinant Human Apolipoprotein A-I/Phospholipids Complex
Product Code: CER-001
Other descriptive name: recombinant human apolipoprotein A-I
Other descriptive name: sphingomyelin
Other descriptive name: 1,2-Dihexadecanoyl-sn-Glycero-3-Phospho-(1-raac-glycerol)
Cerenis TherapeuticsNULLNot RecruitingFemale: yes
Male: yes
30France;United States;Canada;Netherlands;Italy;United Kingdom
2EUCTR2011-003998-28-IT
(EUCTR)
16/02/201208/03/2012Effect of CER-001 on blockage of arteries (plaque) in subjects with homozygous familial hypercholesterolemiaModifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-Label Study of the Effects of CER-001 on Plaque Volume in Subjects with Homozygous Familial Hypercholesterolemia (HoFH) - MODE Homozygous familial hypercholesterolemia
MedDRA version: 15.1;Level: SOC;Classification code 10027433;Term: Metabolism and nutrition disorders;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Recombinant Human Apolipoprotein
Product Code: CER-001
Other descriptive name: Recombinant Human Apolipoprotein A-I
Other descriptive name: Sfingomielina
Other descriptive name: 1,2-Dihexadecanoyl-sn-Glycero-3-Phospho-(1-raac-glycerol)
CERENIS THERAPEUTICS SANULLNot RecruitingFemale: yes
Male: yes
30United States;Canada;Netherlands;United Kingdom;Italy